Accelerating Medicines Partnership® Program - Alzheimer's Disease Phase 1
Revolutionizing knowledge of Alzheimer’s disease to develop better treatments
The Accelerating Medicines Partnership® Program Alzheimer’s Disease Project (AMP® AD) is a precompetitive partnership among government, industry and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets, and on developing biomarkers to help validate existing therapeutic targets for Alzheimer’s disease. This multisector partnership, managed by the Foundation for the NIH, will focus on providing a data-driven approach for identification and validation of biomarkers and disease-relevant targets that will lead to increased clinical trial success.
AMP AD joins five other AMP programs, which are all coordinated by the FNIH, that use cutting-edge scientific approaches to bring new medicines and supports to patients by enhancing validation of novel, clinically relevant therapeutic targets and biomarkers. Click here to learn more about AMP in general. To learn about AMP Type 2 Diabetes click here, AMP RA/SLE Project click here, AMP Parkinson's Disease click here, or AMP Schizophrenia click here.
Read the National Institute on Aging’s (NIA’s) description of the program here.
About Alzheimer’s Disease
Alzheimer’s Disease is a progressive brain disorder that is the most common cause of dementia in older adults. Dementia is the loss of thinking, remembering and reasoning abilities (neuro cognitive functions) to the extent that it interferes with a person’s daily life and activities. It is not a normal part of aging and has many potential causes. Alzheimer’s Disease is characterized by changes in the brain called amyloid plaques and tau tangles as well as a loss of connections between nerve cells (neurons) in the brain. Neurons transmit messages between different parts of the brain, and from the brain to muscles and organs in the body. AMP AD works to further unravel the complex molecular changes involved in Alzheimer’s Disease to speed up identification of novel drug targets. For more information on Alzheimer’s Disease and related dementia’s click here.
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Aging (NIA)
- U.S. Food and Drug Administration (FDA)
Need for New Therapies
There has been a high failure rate of AD drug candidates in end stage clinical trials due to lack of efficacy or unforeseen toxicity that demonstrates the continued need for a deeper understanding of disease complexity and a data-driven approach for identification and validation of disease-relevant targets.
AMP Approach The success of clinical trials aimed at developing new treatments for Alzheimer’s Disease hinges on developing a deeper mechanistic understanding of disease drivers. AMP AD will do so through two projects:
- Biomarkers Project – explores the utility of tau imaging and novel fluid biomarkers for tracking responsiveness to treatment and/or disease progression.
- Target Discovery and Preclinical Validation Project – integrates and shares analysis of large-scale molecular data from human brain samples with network modeling approaches and experimental validation to rapidly identify novel, clinically relevant therapeutic targets
AMP AD Knowledge Portal
Click here to discover and download Alzheimer's Disease data, analyses and tools from AMP AD.
AMP AD Agora Platform
Agora is an open-source platform, created to provide curated AMP-AD verified systems biology analyses showing which genes are associated with Alzheimer's disease (AD). Click here to learn more.
The FNIH has raised a total of $22.2 million in private-sector partner contributions to fund this 5-year AMP AD endeavor. This seeks to leverage NIA contribution of over $162 million, bringing the total combined public- and private-sector commitment to over $185.2 million over five years. This multisector partnership provides participating research organizations with the opportunity to collaborate on a scale that would not be possible for individual partners. Moreover, through close coordination AMP programs allow partner organizations to leverage the substantial scientific and financial resources within their organizations, partner organization, NIH and academia.
Results & Accomplishments
This stage of AMP AD delivered multi-omic data and analytical resources, mechanistic insights, and a systems-based data-driven process for target discovery and validation
- Rich, human, multi-omic data generated and made available to >3000 users to date (60% academia / 40% industry).
- New mechanistic disease insights on role of genome, proteome, metabolome and microbiome established.
- Molecular network models of disease pathways made available.
- Animal models phenotyped and evaluated relative to human molecular networks.
- 542 unique targets nominated and made available through Agora* along with the supporting evidence and extensive druggability information.
- Early experimental validation completed for over 20 candidate targets.
NIA Press Release (October 1, 2019): NIH-funded translational research centers to speed, diversify Alzheimer's drug discovery
Over 200 publications based on AMP-AD datasets, explore publications here
- Feature in Nature Reviews Drug Discovery
- Nature Reviews Drug Discovery (February 27, 2019): Massive NIH-industry project opens portals to target validation - Read more
AMP-AD Data Descriptor Manuscripts: Increasing the Usability of AMP-AD Datasets
- Allen M et al. Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Sci Data. 2016 Oct 11;3:160089. doi: 10.1038/sdata.2016.89. Read more
- De Jager PL et al. A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research. Sci Data. 2018 Aug 7;5:180142. doi: 10.1038/sdata.2018.142. Read more
- Wang M et al. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. Sci Data. 2018 Sep 11;5:180185. doi: 10.1038/sdata.2018.185. Read more
- Ping L et al. Global quantitative analysis of the human brain proteome in Alzheimer's and Parkinson's Disease. Sci Data. 2018 Mar 13;5:180036. doi: 10.1038/sdata.2018.36. Read more
- Barupal DK et al. Generation and quality control of lipidomics data for the Alzheimer’s disease neuroimaging initiative cohort. Sci Data. 2018 Nov 20;5:180263. doi: 10.1038/sdata.2018.263. Read more
- St John-Williams L et al. Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts. Sci Data. 2019 Oct 17;6(1):212. doi: 10.1038/s41597-019-0181-8.
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.